IGKC: A Protein Involved in Neural Circuit Development and Maintenance

Target Name: IGKC

NCBI ID: G3514

Other Name(s): MGC62011 | MGC88770 | MGC72072 | HCAK1 | MGC88809 | immunoglobulin kappa constant | IGKCD | MGC111575 | MGC88771 | Immunoglobulin kappa constant | Km

IGKC: A Protein Involved in Neural Circuit Development and Maintenance

IGKC (MGC62011) is a protein that is expressed in various tissues of the body, including the nervous system, and is involved in the development and maintenance of neural circuits. It is a member of the superfamily of immediate response proteins (SMRs), which are a subclass of the protein kinase C (PKC) family. SMRs are characterized by the presence of a catalytic domain and a short amino terminal extension that is involved in protein-protein interactions.

One of the unique features of IGKC is its ability to interact with other proteins that are involved in the same signaling pathway. This interaction is mediated by the protein kinase A (PKA), which is a key regulator of many cellular processes. When IGKC is activated, it forms a cation-diffusing complex with PKA, which results in the recruitment of other proteins to the site of the interaction. This interaction between IGKC and PKA is critical for the regulation of a wide range of cellular processes, including the development and maintenance of neural circuits.

IGKC has also been shown to play a role in the regulation of ion channels, which are responsible for the flow of electrical current through the cell membrane. In particular, IGKC has been shown to interact with the ion channel protein, K+ channel, to regulate the activity of the channel. This interaction between IGKC and K+ channels is critical for the regulation of muscle contractions and the maintenance of normal heart function.

In addition to its role in the regulation of ion channels, IGKC has also been shown to be involved in the regulation of the nervous system. For example, IGKC has been shown to interact with the neurotransmitter, GABA, and to regulate the activity of the neurotransmitter-gated ion channel, AMPA. This interaction between IGKC and GABA is important for the regulation of the effects of GABA on the nervous system.

IGKC is also involved in the regulation of the cytoskeleton, which is the structure that gives shape to the cell. This interaction between IGKC and the cytoskeleton is critical for the regulation of cell movement and the maintenance of cell shape.

In conclusion, IGKC is a protein that is involved in the regulation of many cellular processes, including the development and maintenance of neural circuits, the regulation of ion channels, the regulation of the nervous system, and the regulation of the cytoskeleton. Its role in these processes makes IGKC an attractive target for drug development. Furthermore, its ability to interact with other proteins that are involved in the same signaling pathway makes it a potential biomarker for a variety of diseases.

Protein Name: Immunoglobulin Kappa Constant

Functions: Constant region of immunoglobulin light chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268)

More Common Targets